Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Wenzhou Yicheng Jingzhan Biotechnology is a Chinese clinical-stage biotechnology company founded in 2024 and based in Zhejiang, China. The company focuses on developing innovative peptide-based therapeutics for inflammatory, autoimmune, and ophthalmic diseases. Its lead candidate, Epivotide (伊匹乌肽), is a first-in-class cell-penetrating peptide inhibitor targeting the p55PIK regulatory subunit of PI3K (encoded by PIK3R3). Epivotide is currently in Phase 2 clinical development for multiple indications, including neurotrophic keratitis, dry eye, and perennial allergic rhinitis.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Wenzhou Yicheng Jingzhan Biotechnology.